Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Nanoparticle targeting of de novo profibrotic macrophages mitigates lung fibrosis

Open access

Abstract

Significance: Current therapies for pulmonary fibrosis (PF) focus on slowing disease progression and reducing functional decline in patients by dampening the activation of fibroblasts and other implicated cells. There is a need for strategies that target the essential cells and signaling pathways involved in disease pathogenesis. Monocyte-derived macrophages (Mo-Macs) are known to express profibrotic genes and are involved in the pathogenesis of PF. Our results show that engineered mannosylated albumin nanoparticles specifically targeted disease-inducing Mo-Macs, and further, that nanoparticles efficiently delivered small-interfering RNA against profibrotic cytokine tumor growth factor β1 to prevent bleomycin-induced lung fibrosis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.2121098119

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1. MANPs bind CD206+ macrophages. (A) Studies were made at baseline (naïve cells) and macrophages obtained from 7 d and 15 d postbleomycin-challenged mice as described in Materials and Methods. These times were chosen since this is window of maximum fibrosis in this model and this period is typically followed by reversal of the disease (17, 19). Results show changes in macrophage profile during development of PF. Tissue resident AM population (SiglecF+ CD11b−) seen in naïve control lungs decreased postbleomycin and this was coupled to the concominant appearance of a new population SiglecF+ CD11b+ AMs, referred to as Mo-AM. (Gating strategy: CD45+Gr1−CD64+). The gating strategy is described in SI Appendix, Fig. S1C. (B) CD206 expression was up-regulated in SiglecF+ AM after bleomycin-induced PF. AM in lung fibrosis acquired higher CD206 expression as compared to naïve AM. All SiglecF+ macrophages were analyzed (gating strategy: CD45+Gr1−CD64+SiglecF+). (C) TGFβ1 expression in AM was up-regulated during peak PF at day 7 and day 15. All SiglecF+ macrophages were analyzed (gating strategy: CD45+Gr1−CD64+SiglecF+). AM during lung fibrosis mice showed augmented TGFβ1 expression as compared AM in naïve mice paralleling the increase in CD206 (B). (D) Scheme for formulation of MANPs to be used in subsequent studies. The formulation involved first synthetizing naked ANPs and then conjugating mannose (as described in Materials and Methods). (E and F) SEM images showing the size and distribution of MANPs with different concentrations of mannose surface coating (Scale bar, 500 nm.) Changes in diameter of nanoparticles as a function of mannose coating as assessed by SEM. Nanoparticles (n = 100) in each condition were analyzed. (G) 1N NMR confirming the peaks of mannose in synthetized MANPs as compared to control ANP and free mannose. (H) Reduction in binding of CD206 to MANPs dependent on the concentration of anti-CD206 antibody. In contrast, this antibody had no effect on the interaction of CD206+ macrophages with ANP. These studies were made using BMDMs (n = 3). Statistical analysis by one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.
Fig. 1. MANPs bind CD206+ macrophages. (A) Studies were made at baseline (naïve cells) and macrophages obtained from 7 d and 15 d postbleomycin-challenged mice as described in Materials and Methods. These times were chosen since this is window of maximum fibrosis in this model and this period is typically followed by reversal of the disease (17, 19). Results show changes in macrophage profile during development of PF. Tissue resident AM population (SiglecF+ CD11b−) seen in naïve control lungs decreased postbleomycin and this was coupled to the concominant appearance of a new population SiglecF+ CD11b+ AMs, referred to as Mo-AM. (Gating strategy: CD45+Gr1−CD64+). The gating strategy is described in SI Appendix, Fig. S1C. (B) CD206 expression was up-regulated in SiglecF+ AM after bleomycin-induced PF. AM in lung fibrosis acquired higher CD206 expression as compared to naïve AM. All SiglecF+ macrophages were analyzed (gating strategy: CD45+Gr1−CD64+SiglecF+). (C) TGFβ1 expression in AM was up-regulated during peak PF at day 7 and day 15. All SiglecF+ macrophages were analyzed (gating strategy: CD45+Gr1−CD64+SiglecF+). AM during lung fibrosis mice showed augmented TGFβ1 expression as compared AM in naïve mice paralleling the increase in CD206 (B). (D) Scheme for formulation of MANPs to be used in subsequent studies. The formulation involved first synthetizing naked ANPs and then conjugating mannose (as described in Materials and Methods). (E and F) SEM images showing the size and distribution of MANPs with different concentrations of mannose surface coating (Scale bar, 500 nm.) Changes in diameter of nanoparticles as a function of mannose coating as assessed by SEM. Nanoparticles (n = 100) in each condition were analyzed. (G) 1N NMR confirming the peaks of mannose in synthetized MANPs as compared to control ANP and free mannose. (H) Reduction in binding of CD206 to MANPs dependent on the concentration of anti-CD206 antibody. In contrast, this antibody had no effect on the interaction of CD206+ macrophages with ANP. These studies were made using BMDMs (n = 3). Statistical analysis by one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001.CC BY · PubMed Central
Fig. 2. MANP uptake is dependent on the activation state of macrophages. (A) Schematic showing the generation of inflammmatory (M1) and antiinflammatory (M2) macrophages; studies were made using AF647 flurophore labeled MANPs to address interaction with BMDMs as described in Materials and Methods. (B) Internalization of AF647 dye-labeled MANPs by M0 (refers to basal untreated macrophages), M1, and M2 macrophages as determined by flow cytometry (n = 3). Uptake of MANPs in M2 macrophages was significantly greater than the other two groups of macrophages. (C) Internalization of MANPS by M2 macrophages was also significantly greater than uptake of nonmannosylated ANP by the same M2 macrophages (n = 3): (i) overlayed flowplots, (ii) quantification. (D and E) Monodansyl cadaverine, inhibitor of receptor-mediated endocytosis (56), in a concentration-dependent manner prevented MANP internalization by M2 macrophages as shown by confocal microscopy (D) and flow cytometry (E): (i) overlayed flowplots, (ii) quantifcation (n = 3). (F) Scheme of workflow to assess the distribution of AF647-labeled MANPs following bleomycin-induced lung fibrosis. (G) MANP+ SiglecF+ AM population in naïve unchallenged mice and in AMs during the zenith of lung fibrosis on day 7 and day 15 postbleomycin. MANPs were largely taken up by Mo-AMs (n = 3 animals for each group) and lung fibrosis significantly augmented the uptake of MANPs. (H) Comparison of MANP uptake by different macrophage populations after induction of PF (n = 6 animals). Comparisons were made among CD64+ SiglecF+ CD11b− macrophages defined as long-term tissue resident AMs, SiglecF+ CD11b+ macrophages defined as newly arrived Mo-AMs, and SiglecF− CD11b+ macrophages defined as Mo-IMs. MANPs at the 5- and 15-d peaks of fibrosis were most internalized by Mo-AMs and relatively fewer were internalized by resident AMs, as well as by transitional Mo-IMs. (I) Study showing uptake of MANPs by Cx3Cr1+ macrophages in Cx3cr1CreERT2 lineage mice. First panel (Gating strategy: CD45+Gr1−CD64+) representing all lung macrophages. Second panel (gating strategy: CD45+Cx3cr1+Gr1−CD64+) representing Cx3cr1+ monocyte-derived lung macrophages. Third panel shows overlay of all lung macrophages (gating strategy: CD45+Gr1−CD64+) (gray) and MANP+ macrophages (CD45+Gr1−CD64+MANP+) (cyan); results show association of MANP+ macrophages with Cx3cr1+ Mo-Macs. Statistical analysis was done by t test analysis and one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Fig. 2. MANP uptake is dependent on the activation state of macrophages. (A) Schematic showing the generation of inflammmatory (M1) and antiinflammatory (M2) macrophages; studies were made using AF647 flurophore labeled MANPs to address interaction with BMDMs as described in Materials and Methods. (B) Internalization of AF647 dye-labeled MANPs by M0 (refers to basal untreated macrophages), M1, and M2 macrophages as determined by flow cytometry (n = 3). Uptake of MANPs in M2 macrophages was significantly greater than the other two groups of macrophages. (C) Internalization of MANPS by M2 macrophages was also significantly greater than uptake of nonmannosylated ANP by the same M2 macrophages (n = 3): (i) overlayed flowplots, (ii) quantification. (D and E) Monodansyl cadaverine, inhibitor of receptor-mediated endocytosis (56), in a concentration-dependent manner prevented MANP internalization by M2 macrophages as shown by confocal microscopy (D) and flow cytometry (E): (i) overlayed flowplots, (ii) quantifcation (n = 3). (F) Scheme of workflow to assess the distribution of AF647-labeled MANPs following bleomycin-induced lung fibrosis. (G) MANP+ SiglecF+ AM population in naïve unchallenged mice and in AMs during the zenith of lung fibrosis on day 7 and day 15 postbleomycin. MANPs were largely taken up by Mo-AMs (n = 3 animals for each group) and lung fibrosis significantly augmented the uptake of MANPs. (H) Comparison of MANP uptake by different macrophage populations after induction of PF (n = 6 animals). Comparisons were made among CD64+ SiglecF+ CD11b− macrophages defined as long-term tissue resident AMs, SiglecF+ CD11b+ macrophages defined as newly arrived Mo-AMs, and SiglecF− CD11b+ macrophages defined as Mo-IMs. MANPs at the 5- and 15-d peaks of fibrosis were most internalized by Mo-AMs and relatively fewer were internalized by resident AMs, as well as by transitional Mo-IMs. (I) Study showing uptake of MANPs by Cx3Cr1+ macrophages in Cx3cr1CreERT2 lineage mice. First panel (Gating strategy: CD45+Gr1−CD64+) representing all lung macrophages. Second panel (gating strategy: CD45+Cx3cr1+Gr1−CD64+) representing Cx3cr1+ monocyte-derived lung macrophages. Third panel shows overlay of all lung macrophages (gating strategy: CD45+Gr1−CD64+) (gray) and MANP+ macrophages (CD45+Gr1−CD64+MANP+) (cyan); results show association of MANP+ macrophages with Cx3cr1+ Mo-Macs. Statistical analysis was done by t test analysis and one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.CC BY · PubMed Central
Fig. 3. Uptake of MANPs by CD206+ Mo-Macs in lungs and transfer of fibrosis induced by CD206+ macrophage injection into naïve lungs. (A) Uptake of MANPs is associated with expression of CD206, TGFβ1, Arg1, and IL-1β at both 7 d and 15 d postbleomycin-induced lung fibrosis. Results show quantitative PCR differences in relative mRNA expression in MANP+ AMs vs. MANP− AMs at 7 d or 15 d after induction of fibrosis using bleomycin; (i) CD206, (ii) TGFβ1, (iii) Arg1, (iv) IL-1β. Fold-changes in expression were calculated relative to 18S rRNA gene and determined by comparative Ct method. Data points represent results from individual mice (n = 3 mice). (B) Scheme for the adoptive transfer experiment used to address effects of transferring MANP+ AMs and MANP− AMs into naïve primed lungs. (C) Lung images showing differences between control mice, MANP− AM transferred mice, and MANP+ AM transferred mice. Fibrosis was only induced by transferring MANP+ AM into naïve lungs. (D) Flow cytometry dot-plot representing profiles of lung macrophages (CD45+Gr1−CD64+) in control mice, MANP− AM-injected mice, and MANP+ AM-injected mice. Results show that MANP+ AM transferred mice induced depletion of tissue resident AM and concomitant influx of Mo-AM. (E) Pdgfrb+ fibroblasts (CD45− Pdgfrb+) in different groups showing relative number of fibroblasts in control, MANP−-transferred mice, and MANP+-transferred mice: (i) overlayed flowplots, (ii) quantification from three independent experiments. Fibroblasts were associated to a greater extent with the MANP+ AM population. (F, i) Histological images of lungs using H&E and Trichome staining in control group, MANP− AM-transferred group, and MANP+ AM-transferred group. Transfer of MANP+ AM-induced lung fibrosis in recipient mice in contrast to MANP− AM indicating that MANP+ AM (which are also CD206+, TGFβ1+, Arg1+, and IL-1β+) recapitulate fibrosis in naïve mice. (ii) Quantification of percentage of fibrotic mass from three independent experiments. Quantification was done using ImageJ. (G) In vivo imaging using in vivo imaging system (IVIS) of different organs at 2 h, 5 d, and 10 d postinjection of AF647-MANPs showing the highest localization in lungs. Besides lungs where MANPs persisted up to 10 d postbleomycin (time of maximum fibrosis), the liver and spleen also showed uptake of MANPs but only at 5 d indicating spillover of MANPs into these peripheral organs. (H) In vivo distribution of AF647-MANPs in lung immune cells in 7 d lung fibrotic mice (n = 7 animals). The gating strategy of immune cells was following: macrophages = CD45+Gr1−CD64+; monocytes = CD45+Ly6G−MHCII−CD64+CD11b+; dendritic cells: CD45+Ly6G−CD64−MHCII+; eosinophils: CD1b−CD45+Ly6G−CD64−MHCII−CD11b+; NK cells = CD45+Ly6G−MHCII−CD64−CD11b+. These results showed highest uptake of MANPs by Mo-IM and Mo-AM. Statistical analysis was carried out by One-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Fig. 3. Uptake of MANPs by CD206+ Mo-Macs in lungs and transfer of fibrosis induced by CD206+ macrophage injection into naïve lungs. (A) Uptake of MANPs is associated with expression of CD206, TGFβ1, Arg1, and IL-1β at both 7 d and 15 d postbleomycin-induced lung fibrosis. Results show quantitative PCR differences in relative mRNA expression in MANP+ AMs vs. MANP− AMs at 7 d or 15 d after induction of fibrosis using bleomycin; (i) CD206, (ii) TGFβ1, (iii) Arg1, (iv) IL-1β. Fold-changes in expression were calculated relative to 18S rRNA gene and determined by comparative Ct method. Data points represent results from individual mice (n = 3 mice). (B) Scheme for the adoptive transfer experiment used to address effects of transferring MANP+ AMs and MANP− AMs into naïve primed lungs. (C) Lung images showing differences between control mice, MANP− AM transferred mice, and MANP+ AM transferred mice. Fibrosis was only induced by transferring MANP+ AM into naïve lungs. (D) Flow cytometry dot-plot representing profiles of lung macrophages (CD45+Gr1−CD64+) in control mice, MANP− AM-injected mice, and MANP+ AM-injected mice. Results show that MANP+ AM transferred mice induced depletion of tissue resident AM and concomitant influx of Mo-AM. (E) Pdgfrb+ fibroblasts (CD45− Pdgfrb+) in different groups showing relative number of fibroblasts in control, MANP−-transferred mice, and MANP+-transferred mice: (i) overlayed flowplots, (ii) quantification from three independent experiments. Fibroblasts were associated to a greater extent with the MANP+ AM population. (F, i) Histological images of lungs using H&E and Trichome staining in control group, MANP− AM-transferred group, and MANP+ AM-transferred group. Transfer of MANP+ AM-induced lung fibrosis in recipient mice in contrast to MANP− AM indicating that MANP+ AM (which are also CD206+, TGFβ1+, Arg1+, and IL-1β+) recapitulate fibrosis in naïve mice. (ii) Quantification of percentage of fibrotic mass from three independent experiments. Quantification was done using ImageJ. (G) In vivo imaging using in vivo imaging system (IVIS) of different organs at 2 h, 5 d, and 10 d postinjection of AF647-MANPs showing the highest localization in lungs. Besides lungs where MANPs persisted up to 10 d postbleomycin (time of maximum fibrosis), the liver and spleen also showed uptake of MANPs but only at 5 d indicating spillover of MANPs into these peripheral organs. (H) In vivo distribution of AF647-MANPs in lung immune cells in 7 d lung fibrotic mice (n = 7 animals). The gating strategy of immune cells was following: macrophages = CD45+Gr1−CD64+; monocytes = CD45+Ly6G−MHCII−CD64+CD11b+; dendritic cells: CD45+Ly6G−CD64−MHCII+; eosinophils: CD1b−CD45+Ly6G−CD64−MHCII−CD11b+; NK cells = CD45+Ly6G−MHCII−CD64−CD11b+. These results showed highest uptake of MANPs by Mo-IM and Mo-AM. Statistical analysis was carried out by One-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.CC BY · PubMed Central
Fig. 4. TGFβ1 siRNA incorporated in MANPs targets fibrogenic Mo-AM. (A) Emission spectrum of Cy5-TGFβ1 siRNA MANPs showing entrapment of siRNA in MANP. (B–D) SEM of MANPs at different pH conditions for 3 h. Diameter of MANPs at different pH values imaged by SEM. Hydrodynamic size of MANPs measured by dynamic light scattering at pH 7.4, 4.5, and 8.5. (Scale bars in B, 200 nm for pH 4.5 and pH 8.5, and 100 nm for pH 7.4.) (E and F) Confocal microscopy images showing escape of Cy5-labeled TGFβ1 siRNA from MANPs and lysosomes within 6 h of posttreatment. Results show release of Cy5 from MANPs at 6 h. (F) Mander’s colocalization coefficient calculated from confocal microscopy images from E; this indicates the fraction of Cy5-siRNA overlapping with Lysotracker red, indicating initial high localization of TGFβ1 siRNA in lysosomes and gradual reduction with time. (G) Expression of TGFβ1 in MANP+ and MANP− Mo-AMs before and after treatment of mice with TGFβ1 siRNA-MANPs. Treatment was carried out on day 3 postbleomycin induction of fibrosis and mice were killed on day 7. (i) Histoplot, (ii) quantification (n = 3 animals). Statistical analysis was carried out by one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Fig. 4. TGFβ1 siRNA incorporated in MANPs targets fibrogenic Mo-AM. (A) Emission spectrum of Cy5-TGFβ1 siRNA MANPs showing entrapment of siRNA in MANP. (B–D) SEM of MANPs at different pH conditions for 3 h. Diameter of MANPs at different pH values imaged by SEM. Hydrodynamic size of MANPs measured by dynamic light scattering at pH 7.4, 4.5, and 8.5. (Scale bars in B, 200 nm for pH 4.5 and pH 8.5, and 100 nm for pH 7.4.) (E and F) Confocal microscopy images showing escape of Cy5-labeled TGFβ1 siRNA from MANPs and lysosomes within 6 h of posttreatment. Results show release of Cy5 from MANPs at 6 h. (F) Mander’s colocalization coefficient calculated from confocal microscopy images from E; this indicates the fraction of Cy5-siRNA overlapping with Lysotracker red, indicating initial high localization of TGFβ1 siRNA in lysosomes and gradual reduction with time. (G) Expression of TGFβ1 in MANP+ and MANP− Mo-AMs before and after treatment of mice with TGFβ1 siRNA-MANPs. Treatment was carried out on day 3 postbleomycin induction of fibrosis and mice were killed on day 7. (i) Histoplot, (ii) quantification (n = 3 animals). Statistical analysis was carried out by one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.CC BY · PubMed Central
Fig. 5. TGFβ1 siRNA incorporated in MANPs mitigates lung fibrosis. (A) Scheme of workflow for therapeutic evaluation of TGFβ1 siRNA-MANPs. (B) Histology of lungs from naïve mice, mice at day 15 postfibrosis induced by bleomycin, and MANP (scrambled and TGFβ1 siRNA) -treated mice at day 15 postfibrosis induced by bleomycin. Tissues were assessed by H&E, Trichome staining and α-SMA staining. (C) Quantification of relative expression of α-SMA from histological images in independent experiments. Quantification was made using ImageJ. (D) Expression of TGFβ1 in Mo-AM after 7 d and 15 d postfibrosis with and without treatment with siRNA-MANP. (E) Micrographs show lung fibrosis induced by bleomycin at day 15 as compared to naïve mice and mice treated TGFβ1-siRNA-MANPs or TGFβ1 scrambled siRNA-MANP–treated mice. (F) Hydroxyproline assay showing collagen content in lungs of naïve, 15 d postfibrosis, 15 d TGFβ1-siRNA-MANP treated and 15 d scrambled siRNA-MANP treated mice. (G) ELISA showing levels of cytokines of (i) TGFβ1 and (ii) IL-1β in lung tissue homogenates. (H) mRNA expression of (i) CD206, (ii) IL-1β, and (iii) Arg1 in naïve, 15-d fibrotic mice, and 15-d fibrotic TGFβ1 siRNA-MANPs–treated mice. Fold-change in expression was calculated relative to 18S rRNA gene, determined by comparative Ct method. Each data point represents results from macrophages pooled from two mice. Statistical analysis was carried out by one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
Fig. 5. TGFβ1 siRNA incorporated in MANPs mitigates lung fibrosis. (A) Scheme of workflow for therapeutic evaluation of TGFβ1 siRNA-MANPs. (B) Histology of lungs from naïve mice, mice at day 15 postfibrosis induced by bleomycin, and MANP (scrambled and TGFβ1 siRNA) -treated mice at day 15 postfibrosis induced by bleomycin. Tissues were assessed by H&E, Trichome staining and α-SMA staining. (C) Quantification of relative expression of α-SMA from histological images in independent experiments. Quantification was made using ImageJ. (D) Expression of TGFβ1 in Mo-AM after 7 d and 15 d postfibrosis with and without treatment with siRNA-MANP. (E) Micrographs show lung fibrosis induced by bleomycin at day 15 as compared to naïve mice and mice treated TGFβ1-siRNA-MANPs or TGFβ1 scrambled siRNA-MANP–treated mice. (F) Hydroxyproline assay showing collagen content in lungs of naïve, 15 d postfibrosis, 15 d TGFβ1-siRNA-MANP treated and 15 d scrambled siRNA-MANP treated mice. (G) ELISA showing levels of cytokines of (i) TGFβ1 and (ii) IL-1β in lung tissue homogenates. (H) mRNA expression of (i) CD206, (ii) IL-1β, and (iii) Arg1 in naïve, 15-d fibrotic mice, and 15-d fibrotic TGFβ1 siRNA-MANPs–treated mice. Fold-change in expression was calculated relative to 18S rRNA gene, determined by comparative Ct method. Each data point represents results from macrophages pooled from two mice. Statistical analysis was carried out by one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.CC BY · PubMed Central
Fig. 6. TGFβ1 siRNA incorporation in MANPs restores lung function and reverses fibrosis. (A) Lung function determination using flexiVent system on 15 d after bleomycin-induced PF. (i) Inspiratory capacity, (ii) respiratory system compliance, (iii) respiratory system resistance, (iv) respiratory system elastance, (v) tissue elastance, (vi) quasi-static compliance, and (vii) tissue dampening. Dots in plot shows values obtained from individual mice. (B,i) Schematic of treatment schedule for 21day fibrosis mice. (ii) Changes in macrophage profile after treatment at 21 d of fibrosis. (iii) Histological evaluation by H&E staining and Trichome staining to detect therapeutic effect. (iv) Quantification of percent fibrotic mass from Trichome staining of histology samples from three independent experiments. The quantification was done using ImageJ. (C) Scheme representation showing actions of MANPs in targeting the fibrosis-inducing Mo-AMs population. Induction of fibrosis involves Mo-AM–mediated release of profibrotic cytokines that activate endothelial cells and fibroblasts toward profibrotic phenotype leading to fibrosis (10). We demonstrated that MANPs targeting of profibrotic Mo-AMs since using TGFβ1 siRNA incorporating MANPs mitigated fibrosis. Statistical analysis was carried out by one-way ANOVA. *P < 0.05; **P < 0.01.
Fig. 6. TGFβ1 siRNA incorporation in MANPs restores lung function and reverses fibrosis. (A) Lung function determination using flexiVent system on 15 d after bleomycin-induced PF. (i) Inspiratory capacity, (ii) respiratory system compliance, (iii) respiratory system resistance, (iv) respiratory system elastance, (v) tissue elastance, (vi) quasi-static compliance, and (vii) tissue dampening. Dots in plot shows values obtained from individual mice. (B,i) Schematic of treatment schedule for 21day fibrosis mice. (ii) Changes in macrophage profile after treatment at 21 d of fibrosis. (iii) Histological evaluation by H&E staining and Trichome staining to detect therapeutic effect. (iv) Quantification of percent fibrotic mass from Trichome staining of histology samples from three independent experiments. The quantification was done using ImageJ. (C) Scheme representation showing actions of MANPs in targeting the fibrosis-inducing Mo-AMs population. Induction of fibrosis involves Mo-AM–mediated release of profibrotic cytokines that activate endothelial cells and fibroblasts toward profibrotic phenotype leading to fibrosis (10). We demonstrated that MANPs targeting of profibrotic Mo-AMs since using TGFβ1 siRNA incorporating MANPs mitigated fibrosis. Statistical analysis was carried out by one-way ANOVA. *P < 0.05; **P < 0.01.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Research works printed but not linked: 1

  1. Health NIo, Idiopathic Pulmonary Fibrosis Frequency (US National Library of Medicine, 2020).

Cited by

See all 107

Metadata

Authors
Singh, A., Chakraborty, S., Wong, S. W., Hefner, N. A., Stuart, A., Qadir, A. S., Mukhopadhyay, A., Bachmaier, K., Shin, J.-W., Rehman, J., & Malik, A. B.
Affiliations
University of Illinois Chicago (US)
Corresponding author
Malik, Asrar B.
Venue
Proceedings of the National Academy of Sciences
Published
2022-04-04
Volume
119
Issue
15
Pages
e2121098119-e2121098119
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W4224117100
Cited by
107
References
57
Citations by year
2026: 22 · 2025: 34 · 2024: 24 · 2023: 20 · 2022: 7
FWCI
13.70
Type
journal article
Language
en
Open access
Locations
  • Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • HHS | NIH | National Heart, Lung, and Blood Institute (T32HL007829, R41HL126456, R42HL126456, P01HL151327, R01HL141255)
  • HHS | NIH | National Institute of General Medical Sciences (R01GM141147)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
pulmonary fibrosis, macrophage targeting, TGF-β1, siRNA delivery, monocyte-derived macrophages, alveolar macrophages, interstitial macrophages, nanoparticle uptake, extracellular matrix remodeling, antifibrotic therapy
MeSH terms
Mannose Receptor, Animals, Bleomycin, Disease Models, Animal, Lymphotoxin-alpha, Mice, Inbred C57BL, Pulmonary Fibrosis, Macrophages, Alveolar, RNA, Small Interfering, Mice, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nanoparticle targeting of de novo profibrotic macrophages mitigates lung fibrosis. https://app.cochat.ai/papers/10.1073/pnas.2121098119
The paper
Singh, A., Chakraborty, S., Wong, S. W., Hefner, N. A., Stuart, A., Qadir, A. S., Mukhopadhyay, A., Bachmaier, K., Shin, J.-W., Rehman, J., & Malik, A. B. (2022). Nanoparticle targeting of de novo profibrotic macrophages mitigates lung fibrosis. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2121098119

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.